Valuation: Immatics N.V.

Market Cap 920M 818M 758M 690M 1.3B 87.31B 1.32B 9.11B 3.57B 45.56B 3.45B 3.38B 145B P/E 2026 *
-3.22x
P/E 2027 * -3.28x
Enterprise Value 634M 563M 522M 475M 896M 60.15B 911M 6.28B 2.46B 31.39B 2.38B 2.33B 100B EV / Sales 2026 *
13.9x
EV / Sales 2027 * 14.6x
Free-Float
76.83%
Yield 2026 *
-
Yield 2027 * -
1 day-5.74%
1 week-9.42%
Current month-23.35%
1 month-23.70%
3 months-29.82%
6 months-39.75%
Current year-35.90%
1 week 6.65
Extreme 6.65
7.42
1 month 6.65
Extreme 6.65
9.16
Current year 6.65
Extreme 6.65
11.94
1 year 6.65
Extreme 6.65
12.41
3 years 3.3
Extreme 3.3
13.77
5 years 3.3
Extreme 3.3
14.9
10 years 0
Extreme 0
18.42
Manager TitleAgeSince
Chief Executive Officer 51 01/01/2019
Director of Finance/CFO 57 01/10/2025
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 51 01/07/2020
Chairman 70 01/10/2012
Director/Board Member 72 01/07/2020
Date Insider Type Main position Quantity % Market Cap. Importance
26/8/26
Perceptive Advisors LLC
BuyCompany 863,060 0.6436%
18/3/26 Other

Chief Financial Officer

350,000 0.2611%
18/3/26 Other

Head of Human Resources

211,000 0.1574%
Change 5-day change 1-year change 3-year change Capi.($)
-5.74%-9.42%-31.81%-32.63% 920M
-6.60%-8.56%+49.38%+63.51% 65B
+0.03%+5.56%+9.10%+69.05% 51.2B
-4.09%-0.11%+2.22%+53.15% 51.19B
-1.53%+2.70%+30.48%+34.12% 43.93B
-1.34%+4.12%+16.64%+115.13% 41.96B
-5.97%-6.22%+228.95%+454.22% 38.14B
+6.53%+8.02%+16.40%+53.41% 33.24B
-0.90%-10.49%+37.09%-3.70% 25.2B
-1.07%+2.33%+19.43%+9.98% 22.5B
Average -2.07%-1.26%+37.79%+81.62% 37.33B
Weighted average by Cap. -2.20%-0.52%+44.06%+96.22%

Financials

2026 *2027 *
Net sales 45.73M 40.65M 37.67M 34.28M 64.68M 4.34B 65.72M 453M 178M 2.26B 172M 168M 7.22B 39.73M 35.32M 32.74M 29.78M 56.2M 3.77B 57.1M 393M 154M 1.97B 149M 146M 6.27B
Net income -287M -255M -237M -215M -406M -27.25B -413M -2.84B -1.11B -14.22B -1.08B -1.05B -45.33B -313M -279M -258M -235M -443M -29.75B -451M -3.1B -1.22B -15.53B -1.18B -1.15B -49.5B
Net Debt -286M -254M -236M -215M -405M -27.16B -411M -2.83B -1.11B -14.17B -1.07B -1.05B -45.18B -339M -301M -279M -254M -479M -32.15B -487M -3.35B -1.32B -16.77B -1.27B -1.24B -53.48B
Projected Income Statement - Annual - Immatics N.V.
Logo Immatics N.V.
Immatics N.V. is a clinical-stage biopharmaceutical company. The Company is primarily engaged in precision targeting of PRAME with multiple clinical-stage programs spanning cell therapies and bispecifics.PRAME is a target expressed approximately 50 cancers. Its PRAME franchise includes approximately three product candidates, two therapeutic modalities and three combination therapies that target PRAME: anzu-cel (anzutresgene autoleucel, IMA203) PRAME cell therapy, IMA203CD8 PRAME cell therapy, IMA402 PRAME bispecific as monotherapy, in combination with immune checkpoint inhibitors, in combination with IMA401 MAGEA4/8 bispecific as well as anzu-cel in combination with Moderna’s PRAME mRNA designed to enhance cell therapy. The Company has approximately two technology platforms for target and T Cell Receptor (TCR) discovery.
Employees
704
Date Price Change Volume
16/10/26 US$6.730 -5.74% 1,154,934
15/10/26 US$7.140 +2.00% 1,629,203
14/10/26 US$7.000 +2.49% 1,566,889
13/10/26 US$6.830 -5.27% 928,583
12/10/26 US$7.210 -2.96% 750,365
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Immatics N.V.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
6.730USD
Average target price
17.26USD
Spread / Average Target
+156.42%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Immatics N.V.
  1. Stock Market
  2. Stocks
  3. IMTX Stock